跳至主要内容
临床试验/NCT06772740
NCT06772740招募中不适用

Randomized Clinical Trial of Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma (COMPLEMENT Study)

Kazutaka Uchida1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2024年12月23日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
600
试验地点
1
主要终点
Rate of recurrence of chronic subdural hematoma

研究概览

简要总结

COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • pre-mRS 0-3
  • Hematoma thickness >=10mm
  • Having at least one risk factor Risk factor: Age >=75, Antithrombotic therapy, DM, Bilateral hematoma, Markwalder grading score >3, Preoperative volume >=130ml, Preoperative midline shift >=8mm, CT appearance (Homogeneous, laminar or separated)

排除标准

  • Plt <50,000, PT-INR >2
  • Life expectancy <6 months

研究组 & 干预措施

Conventional treatments with middle meningeal artery embolization

Experimental

干预措施: Middle meningeal artery embolization (Procedure)

Conventional treatments alone

No Intervention

结局指标

主要结局

Rate of recurrence of chronic subdural hematoma

时间窗: 6 months after randomization

Recurrence of chronic subdural hematoma is defined as the maximum thickness of subdural hematoma exceeding 10 mm or the patient receiving re-operation.

次要结局

未报告次要终点

研究者

发起方
Kazutaka Uchida
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Kazutaka Uchida

Associate Professor (Stroke Center)

Hyogo Medical University

研究点 (1)

Loading locations...

相似试验